Shrimp Disease Diagnostics Market by Technology (Enzyme Linked Immunosorbent Assay, Loop Mediated Isothermal Amplification, Next Generation Sequencing), Diagnostic Method (Histopathological Diagnostics, Immunological Diagnostics, Microbiological Diagnosti
Description
The Shrimp Disease Diagnostics Market was valued at USD 478.11 million in 2024 and is projected to grow to USD 507.55 million in 2025, with a CAGR of 8.14%, reaching USD 894.81 million by 2032.
An authoritative orientation to contemporary shrimp disease diagnostics that frames technological advances, field realities, and operational challenges for decision-makers
The shrimp disease diagnostics landscape sits at the intersection of aquaculture sustainability, veterinary science, and molecular technology innovation. As global production systems intensify and pathogens evolve, diagnostic capacity has become a foundational component of biosecurity strategies and research agendas. Rapid, reliable detection enables earlier interventions, reduces downstream losses, and supports compliance with trade and certification frameworks, making diagnostics an essential operational capability for producers, laboratories, and policy planners alike.
Recent advances in assay design, sample processing, and data analytics have expanded the toolkit available to practitioners while also raising expectations for specificity, throughput, and field deployability. At the same time, stakeholders face persistent challenges including diagnostic standardization, laboratory infrastructure deficits in some production regions, and the need to translate molecular outputs into practical management actions. This introduction sets the scene for an executive summary that synthesizes technological, regulatory, and commercial forces shaping the sector and identifies where operational leaders should concentrate resources to strengthen disease detection and control.
How innovation, decentralization, and integrated data systems are redefining diagnostic expectations and operational models across shrimp health management
The landscape of shrimp disease diagnostics is undergoing transformative shifts driven by convergence of high-resolution molecular tools, decentralized testing capacity, and integrated data ecosystems. Technologies that were once confined to centralized laboratories are increasingly miniaturized and adapted for on-farm or near-shore deployment, accelerating the pace at which actionable results reach production managers. Concurrently, sequencing and bioinformatics have moved beyond pathogen identification to enable deeper insights into strain diversity, pathogen evolution, and resistance markers, thereby reshaping surveillance strategies and research priorities.
Operational models are also evolving: diagnostic service providers are integrating advisory services and data interpretation into their offerings, while collaborations between academic institutions, research centers, and industry actors are expanding the evidence base for intervention strategies. Regulatory frameworks and certification bodies are adapting to incorporate newer diagnostic modalities, which, in turn, drives demand for validated assays and standardized protocols. Taken together, these shifts are elevating expectations for speed, accuracy, and interpretability, and they are creating new pathways for translating diagnostic intelligence into proactive disease management.
Trade policy shifts and cumulative tariff effects prompting supply chain realignment, supplier diversification, and greater emphasis on domestic diagnostic resilience
Cumulative tariff measures enacted by major trading partners have exerted pressure on cross-border flows of diagnostic reagents, specialized consumables, and instrumentation, prompting supply chain recalibration across the diagnostic value chain. Import duties and trade frictions increase lead times for critical laboratory inputs and can raise the cost base for diagnostic service providers, laboratories, and aquaculture operations that rely on imported assays and equipment. In response, procurement leaders have revisited supplier portfolios, sought alternative sourcing arrangements, and accelerated qualification of domestic or regional manufacturers to reduce vulnerability.
Beyond immediate procurement impacts, tariff dynamics have influenced strategic decisions regarding local capacity expansion, maintenance of critical spare parts inventories, and investments in adaptable platforms that can use more widely available reagents. Researchers and providers have also intensified efforts to validate alternative workflows and open-source protocols to mitigate single-supplier risks. From a policy perspective, trade measures have spurred dialogue about harmonizing import regulations for diagnostic supplies to preserve disease surveillance capabilities and international cooperation in aquatic animal health.
Nuanced segmentation across technology, method, application, end user, and disease type that clarifies assay selection, deployment trade-offs, and capability gaps
Segment-level analysis reveals differentiated drivers and adoption patterns across technologies, diagnostic methods, applications, end users, and disease types. Based on technology, assay selection spans Enzyme Linked Immunosorbent Assay, Loop Mediated Isothermal Amplification, Next Generation Sequencing, and Polymerase Chain Reaction, with Polymerase Chain Reaction further differentiated into Multiplex PCR, Quantitative PCR, and Reverse Transcription PCR; these distinctions influence throughput, sensitivity, and suitability for field versus laboratory contexts. In practice, the choice between sequencing and targeted PCR approaches hinges on whether the objective prioritizes comprehensive pathogen discovery or rapid targeted detection, and that decision shapes investment in instrumentation, bioinformatics, and operator training.
When framed by diagnostic method, tools range across histopathological diagnostics, immunological diagnostics, microbiological diagnostics, and molecular diagnostics, where immunological approaches are further characterized by Enzyme Linked Immunosorbent Assay, Lateral Flow Immunoassay, and Western Blot variants; each method carries trade-offs in specificity, turnaround time, and infrastructure requirements, which dictate the preferred use-cases. Application-oriented segmentation highlights monitoring, outbreak investigation, research, and screening as distinct operational intents, and each application imposes different demands on sensitivity, frequency, and reporting workflows. End users include academic institutions, aquaculture farms, diagnostic laboratories, and research institutes, each bringing unique resource constraints, quality requirements, and data utilization practices. Finally, disease-type segmentation distinguishes bacterial, fungal, parasitic, and viral diseases, and this taxonomy informs assay selection, sample handling, and control strategies. Understanding these intersecting segments enables more precise alignment of product development, service design, and capacity-building initiatives to real-world needs.
Region-specific diagnostic priorities and capacity patterns that influence technology adoption, regulatory emphasis, and collaborative surveillance models
Regional dynamics shape diagnostic priorities, infrastructure investment, and collaborative networks in distinct ways. In the Americas, established laboratory networks and vertically integrated aquaculture operations drive demand for high-throughput molecular platforms and comprehensive surveillance protocols, while market actors emphasize traceability and export compliance. The Americas also exhibit active public–private collaboration in disease response and diagnostic validation, which facilitates rapid adoption of standardized assays. Transitioning from these strengths, stakeholders are focused on scaling field-deployable tools to reach smaller producers and remote operations.
In Europe, the Middle East & Africa, regulatory harmonization and stringent animal health standards elevate expectations for assay validation, accreditation, and documentation. Investment in laboratory accreditation and cross-border data sharing supports coordinated outbreak response, yet infrastructure gaps in parts of the region create uneven access to advanced diagnostics. Capacity-building initiatives aim to bridge these divides and promote accessible technologies. The Asia-Pacific region, home to the largest shrimp-producing geographies, faces intense pressure from endemic and emergent pathogens, prompting innovation in rapid diagnostics, decentralized testing, and integrated surveillance systems. Regional stakeholders prioritize technologies that balance sensitivity with cost-effectiveness and that can be embedded into routine farm management practices to reduce disease-driven losses.
How companies and research organizations are evolving through partnerships, platform interoperability, and service integration to meet complex diagnostic needs
Major industry participants and research-focused organizations are expanding their roles beyond single-product offerings toward integrated service models that combine assay provision, data interpretation, and advisory support. Companies are increasingly investing in platform interoperability, validation pipelines, and collaborative trials with academic and field partners to demonstrate assay robustness under diverse operational conditions. These collaborations accelerate credentialing of new tests and support market entry in jurisdictions with strict validation requirements.
At the same time, diagnostic providers are forging partnerships with instrument manufacturers and reagent suppliers to optimize supply continuity and to co-develop kits tailored for aquaculture sample matrices. Service differentiation is emerging through offerings such as remote interpretation, quality-assured sample logistics, and subscription-based monitoring services that align with producer workflows. Research institutions continue to contribute foundational science, while commercial entities translate validated protocols into scalable products, creating a complementary ecosystem that emphasizes both scientific rigor and operational practicality.
Targeted actions for leaders to strengthen supply resilience, validation, workforce capability, and data integration to elevate diagnostic impact
Industry leaders should prioritize investments that enhance diagnostic resilience, field applicability, and data-driven decision-making. First, strengthening supply chain resilience through dual sourcing strategies and regional manufacturing partnerships will reduce exposure to trade disruptions and seasonal bottlenecks. Second, expanding validation efforts across diverse sample types and production contexts will accelerate regulatory acceptance and broaden market applicability. Third, integrating diagnostics with decision support systems and advisory services will increase the utility of test results by translating technical outputs into actionable management plans.
Operationally, leaders should invest in workforce development to ensure technicians and field personnel can execute advanced protocols and interpret molecular outputs. At the same time, establishing transparent data governance frameworks and interoperable reporting standards will facilitate multi-stakeholder collaboration and cross-border surveillance. Finally, targeted investments in decentralized testing platforms and cost-effective assay formats will support broader access among small and medium-sized producers, which is essential to achieving system-level disease control and resilience.
A robust mixed-methods approach combining literature synthesis, validation review, and expert engagement to ensure practical and evidence-based insights
The research methodology for this analysis combined a structured review of peer-reviewed literature, synthesis of recent technical guidelines, and qualitative engagement with subject-matter experts across laboratory, academic, and aquaculture practice domains. Emphasis was placed on triangulating findings from assay validation studies, surveillance reports, and methodological papers to ensure conclusions reflect both technological capabilities and field realities. Expert interviews provided contextual insights into operational constraints, supply chain dynamics, and user priorities that are not always evident in published literature.
Where appropriate, methodological rigor included cross-comparison of diagnostic performance metrics and assessment of implementation pathways for emerging technologies. The approach prioritized transparent reporting of data sources, assumptions, and limitations, and it sought to identify areas where additional primary research or standardized validation would materially improve confidence in diagnostic decision-making. This methodology ensures that the insights presented are actionable, evidence-informed, and aligned with stakeholder needs across the diagnostic ecosystem.
Concluding synthesis that connects technological potential, operational investments, and collaborative validation as keys to durable improvements in shrimp health outcomes
In conclusion, shrimp disease diagnostics occupy a strategic nexus of technological innovation, supply chain considerations, and operational imperatives. Rapid advances in molecular methods and field-deployable assays are creating new opportunities to detect and manage pathogens earlier and more effectively. Yet realizing the full potential of these advances requires coordinated investments in validation, workforce capability, and resilient supply chains, as well as careful attention to data integration and regulatory alignment.
Looking ahead, stakeholders who align technology selection with application-specific requirements, invest in interoperable data systems, and pursue collaborative validation pathways will be best positioned to translate diagnostic intelligence into tangible improvements in animal health and production stability. The cumulative effect of these choices will determine whether diagnostics function merely as isolated tests or as linchpins of comprehensive health management systems.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative orientation to contemporary shrimp disease diagnostics that frames technological advances, field realities, and operational challenges for decision-makers
The shrimp disease diagnostics landscape sits at the intersection of aquaculture sustainability, veterinary science, and molecular technology innovation. As global production systems intensify and pathogens evolve, diagnostic capacity has become a foundational component of biosecurity strategies and research agendas. Rapid, reliable detection enables earlier interventions, reduces downstream losses, and supports compliance with trade and certification frameworks, making diagnostics an essential operational capability for producers, laboratories, and policy planners alike.
Recent advances in assay design, sample processing, and data analytics have expanded the toolkit available to practitioners while also raising expectations for specificity, throughput, and field deployability. At the same time, stakeholders face persistent challenges including diagnostic standardization, laboratory infrastructure deficits in some production regions, and the need to translate molecular outputs into practical management actions. This introduction sets the scene for an executive summary that synthesizes technological, regulatory, and commercial forces shaping the sector and identifies where operational leaders should concentrate resources to strengthen disease detection and control.
How innovation, decentralization, and integrated data systems are redefining diagnostic expectations and operational models across shrimp health management
The landscape of shrimp disease diagnostics is undergoing transformative shifts driven by convergence of high-resolution molecular tools, decentralized testing capacity, and integrated data ecosystems. Technologies that were once confined to centralized laboratories are increasingly miniaturized and adapted for on-farm or near-shore deployment, accelerating the pace at which actionable results reach production managers. Concurrently, sequencing and bioinformatics have moved beyond pathogen identification to enable deeper insights into strain diversity, pathogen evolution, and resistance markers, thereby reshaping surveillance strategies and research priorities.
Operational models are also evolving: diagnostic service providers are integrating advisory services and data interpretation into their offerings, while collaborations between academic institutions, research centers, and industry actors are expanding the evidence base for intervention strategies. Regulatory frameworks and certification bodies are adapting to incorporate newer diagnostic modalities, which, in turn, drives demand for validated assays and standardized protocols. Taken together, these shifts are elevating expectations for speed, accuracy, and interpretability, and they are creating new pathways for translating diagnostic intelligence into proactive disease management.
Trade policy shifts and cumulative tariff effects prompting supply chain realignment, supplier diversification, and greater emphasis on domestic diagnostic resilience
Cumulative tariff measures enacted by major trading partners have exerted pressure on cross-border flows of diagnostic reagents, specialized consumables, and instrumentation, prompting supply chain recalibration across the diagnostic value chain. Import duties and trade frictions increase lead times for critical laboratory inputs and can raise the cost base for diagnostic service providers, laboratories, and aquaculture operations that rely on imported assays and equipment. In response, procurement leaders have revisited supplier portfolios, sought alternative sourcing arrangements, and accelerated qualification of domestic or regional manufacturers to reduce vulnerability.
Beyond immediate procurement impacts, tariff dynamics have influenced strategic decisions regarding local capacity expansion, maintenance of critical spare parts inventories, and investments in adaptable platforms that can use more widely available reagents. Researchers and providers have also intensified efforts to validate alternative workflows and open-source protocols to mitigate single-supplier risks. From a policy perspective, trade measures have spurred dialogue about harmonizing import regulations for diagnostic supplies to preserve disease surveillance capabilities and international cooperation in aquatic animal health.
Nuanced segmentation across technology, method, application, end user, and disease type that clarifies assay selection, deployment trade-offs, and capability gaps
Segment-level analysis reveals differentiated drivers and adoption patterns across technologies, diagnostic methods, applications, end users, and disease types. Based on technology, assay selection spans Enzyme Linked Immunosorbent Assay, Loop Mediated Isothermal Amplification, Next Generation Sequencing, and Polymerase Chain Reaction, with Polymerase Chain Reaction further differentiated into Multiplex PCR, Quantitative PCR, and Reverse Transcription PCR; these distinctions influence throughput, sensitivity, and suitability for field versus laboratory contexts. In practice, the choice between sequencing and targeted PCR approaches hinges on whether the objective prioritizes comprehensive pathogen discovery or rapid targeted detection, and that decision shapes investment in instrumentation, bioinformatics, and operator training.
When framed by diagnostic method, tools range across histopathological diagnostics, immunological diagnostics, microbiological diagnostics, and molecular diagnostics, where immunological approaches are further characterized by Enzyme Linked Immunosorbent Assay, Lateral Flow Immunoassay, and Western Blot variants; each method carries trade-offs in specificity, turnaround time, and infrastructure requirements, which dictate the preferred use-cases. Application-oriented segmentation highlights monitoring, outbreak investigation, research, and screening as distinct operational intents, and each application imposes different demands on sensitivity, frequency, and reporting workflows. End users include academic institutions, aquaculture farms, diagnostic laboratories, and research institutes, each bringing unique resource constraints, quality requirements, and data utilization practices. Finally, disease-type segmentation distinguishes bacterial, fungal, parasitic, and viral diseases, and this taxonomy informs assay selection, sample handling, and control strategies. Understanding these intersecting segments enables more precise alignment of product development, service design, and capacity-building initiatives to real-world needs.
Region-specific diagnostic priorities and capacity patterns that influence technology adoption, regulatory emphasis, and collaborative surveillance models
Regional dynamics shape diagnostic priorities, infrastructure investment, and collaborative networks in distinct ways. In the Americas, established laboratory networks and vertically integrated aquaculture operations drive demand for high-throughput molecular platforms and comprehensive surveillance protocols, while market actors emphasize traceability and export compliance. The Americas also exhibit active public–private collaboration in disease response and diagnostic validation, which facilitates rapid adoption of standardized assays. Transitioning from these strengths, stakeholders are focused on scaling field-deployable tools to reach smaller producers and remote operations.
In Europe, the Middle East & Africa, regulatory harmonization and stringent animal health standards elevate expectations for assay validation, accreditation, and documentation. Investment in laboratory accreditation and cross-border data sharing supports coordinated outbreak response, yet infrastructure gaps in parts of the region create uneven access to advanced diagnostics. Capacity-building initiatives aim to bridge these divides and promote accessible technologies. The Asia-Pacific region, home to the largest shrimp-producing geographies, faces intense pressure from endemic and emergent pathogens, prompting innovation in rapid diagnostics, decentralized testing, and integrated surveillance systems. Regional stakeholders prioritize technologies that balance sensitivity with cost-effectiveness and that can be embedded into routine farm management practices to reduce disease-driven losses.
How companies and research organizations are evolving through partnerships, platform interoperability, and service integration to meet complex diagnostic needs
Major industry participants and research-focused organizations are expanding their roles beyond single-product offerings toward integrated service models that combine assay provision, data interpretation, and advisory support. Companies are increasingly investing in platform interoperability, validation pipelines, and collaborative trials with academic and field partners to demonstrate assay robustness under diverse operational conditions. These collaborations accelerate credentialing of new tests and support market entry in jurisdictions with strict validation requirements.
At the same time, diagnostic providers are forging partnerships with instrument manufacturers and reagent suppliers to optimize supply continuity and to co-develop kits tailored for aquaculture sample matrices. Service differentiation is emerging through offerings such as remote interpretation, quality-assured sample logistics, and subscription-based monitoring services that align with producer workflows. Research institutions continue to contribute foundational science, while commercial entities translate validated protocols into scalable products, creating a complementary ecosystem that emphasizes both scientific rigor and operational practicality.
Targeted actions for leaders to strengthen supply resilience, validation, workforce capability, and data integration to elevate diagnostic impact
Industry leaders should prioritize investments that enhance diagnostic resilience, field applicability, and data-driven decision-making. First, strengthening supply chain resilience through dual sourcing strategies and regional manufacturing partnerships will reduce exposure to trade disruptions and seasonal bottlenecks. Second, expanding validation efforts across diverse sample types and production contexts will accelerate regulatory acceptance and broaden market applicability. Third, integrating diagnostics with decision support systems and advisory services will increase the utility of test results by translating technical outputs into actionable management plans.
Operationally, leaders should invest in workforce development to ensure technicians and field personnel can execute advanced protocols and interpret molecular outputs. At the same time, establishing transparent data governance frameworks and interoperable reporting standards will facilitate multi-stakeholder collaboration and cross-border surveillance. Finally, targeted investments in decentralized testing platforms and cost-effective assay formats will support broader access among small and medium-sized producers, which is essential to achieving system-level disease control and resilience.
A robust mixed-methods approach combining literature synthesis, validation review, and expert engagement to ensure practical and evidence-based insights
The research methodology for this analysis combined a structured review of peer-reviewed literature, synthesis of recent technical guidelines, and qualitative engagement with subject-matter experts across laboratory, academic, and aquaculture practice domains. Emphasis was placed on triangulating findings from assay validation studies, surveillance reports, and methodological papers to ensure conclusions reflect both technological capabilities and field realities. Expert interviews provided contextual insights into operational constraints, supply chain dynamics, and user priorities that are not always evident in published literature.
Where appropriate, methodological rigor included cross-comparison of diagnostic performance metrics and assessment of implementation pathways for emerging technologies. The approach prioritized transparent reporting of data sources, assumptions, and limitations, and it sought to identify areas where additional primary research or standardized validation would materially improve confidence in diagnostic decision-making. This methodology ensures that the insights presented are actionable, evidence-informed, and aligned with stakeholder needs across the diagnostic ecosystem.
Concluding synthesis that connects technological potential, operational investments, and collaborative validation as keys to durable improvements in shrimp health outcomes
In conclusion, shrimp disease diagnostics occupy a strategic nexus of technological innovation, supply chain considerations, and operational imperatives. Rapid advances in molecular methods and field-deployable assays are creating new opportunities to detect and manage pathogens earlier and more effectively. Yet realizing the full potential of these advances requires coordinated investments in validation, workforce capability, and resilient supply chains, as well as careful attention to data integration and regulatory alignment.
Looking ahead, stakeholders who align technology selection with application-specific requirements, invest in interoperable data systems, and pursue collaborative validation pathways will be best positioned to translate diagnostic intelligence into tangible improvements in animal health and production stability. The cumulative effect of these choices will determine whether diagnostics function merely as isolated tests or as linchpins of comprehensive health management systems.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of CRISPR-based point-of-care diagnostic assays for shrimp pathogens enabling faster detection
- 5.2. Integration of AI-powered predictive analytics with shrimp farm telemetry for early disease outbreak alerts
- 5.3. Development of multiplex PCR assays for simultaneous detection of multiple shrimp viral and bacterial diseases
- 5.4. Growing use of portable isothermal amplification devices for on-site shrimp disease monitoring at farms
- 5.5. Implementation of next generation sequencing platforms for comprehensive shrimp pathogen surveillance programs
- 5.6. Emergence of handheld biosensor chips leveraging nanotechnology for rapid shrimp pathogen identification
- 5.7. Expansion of IoT-connected water quality sensors coupled with disease diagnostic tools to optimize shrimp health management
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Shrimp Disease Diagnostics Market, by Technology
- 8.1. Enzyme Linked Immunosorbent Assay
- 8.2. Loop Mediated Isothermal Amplification
- 8.3. Next Generation Sequencing
- 8.4. Polymerase Chain Reaction
- 8.4.1. Multiplex PCR
- 8.4.2. Quantitative PCR
- 8.4.3. Reverse Transcription PCR
- 9. Shrimp Disease Diagnostics Market, by Diagnostic Method
- 9.1. Histopathological Diagnostics
- 9.2. Immunological Diagnostics
- 9.2.1. Enzyme Linked Immunosorbent Assay
- 9.2.2. Lateral Flow Immunoassay
- 9.2.3. Western Blot
- 9.3. Microbiological Diagnostics
- 9.4. Molecular Diagnostics
- 10. Shrimp Disease Diagnostics Market, by Disease Type
- 10.1. Bacterial Diseases
- 10.2. Fungal Diseases
- 10.3. Parasitic Diseases
- 10.4. Viral Diseases
- 11. Shrimp Disease Diagnostics Market, by Application
- 11.1. Monitoring
- 11.2. Outbreak Investigation
- 11.3. Research
- 11.4. Screening
- 12. Shrimp Disease Diagnostics Market, by End User
- 12.1. Academic Institutions
- 12.2. Aquaculture Farms
- 12.3. Diagnostic Laboratories
- 12.4. Research Institutes
- 13. Shrimp Disease Diagnostics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Shrimp Disease Diagnostics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Shrimp Disease Diagnostics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. 3 Little Fish Sdn Bhd
- 16.3.2. Amazing Biotech
- 16.3.3. Aquaintech Inc.
- 16.3.4. Arachem (M) Sdn Bhd
- 16.3.5. Bioneer Corporation
- 16.3.6. Blue Aqua International Pte. Ltd.
- 16.3.7. CD Genomics
- 16.3.8. China Guangzhou BioKey Healthy Technology Co. Ltd
- 16.3.9. DSM Austria GmbH
- 16.3.10. Forte Biotech
- 16.3.11. GeneReach Biotechnology Corp.
- 16.3.12. Genics Pty. Ltd.
- 16.3.13. Innocreate Bioscience Co., Ltd.
- 16.3.14. Lab-Ind Resource Sdn. Bhd.
- 16.3.15. Mahesh Aqua Holdings (Pvt) Ltd.
- 16.3.16. Mylab Discovery Solutions Pvt. Ltd.
- 16.3.17. PT Riset Nusantara Genetika (Nusantics)
- 16.3.18. Reagen LLC
- 16.3.19. Ring Biotechnology Co Ltd.
- 16.3.20. Speedy Assay Sdn. Bhd.
- 16.3.21. SUREBIO
- 16.3.22. Thermo Fisher Scientific Inc.
- 16.3.23. Laboratory Corporation of America Holdings
- 16.3.24. Randox Laboratories Ltd.
- 16.3.25. GeneReach Biotechnology Corporation
- 16.3.26. Illumina, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
